VRAX (Virax Biolabs Group) Short-Term Debt : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group Short-Term Debt?

Virax Biolabs Group's Short-Term Debt for the quarter that ended in Sep. 2024 was $0.00 Mil.

Virax Biolabs Group's annual Short-Term Debt increased from Mar. 2022 ($0.00 Mil) to Mar. 2023 ($0.15 Mil) but then declined from Mar. 2023 ($0.15 Mil) to Mar. 2024 ($0.00 Mil).

Virax Biolabs Group Short-Term Debt Historical Data

The historical data trend for Virax Biolabs Group's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group Short-Term Debt Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

Short-Term Debt

0.15

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Short-Term Debt	Get a 7-Day Free Trial					0.39	0.15	-	-	-

Virax Biolabs Group Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Virax Biolabs Group Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.